SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
News
ATRC
--
0.00%
--
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18)
Benzinga · 05/19 12:27
Stocks That Hit 52-Week Highs On Monday
During the morning session on Monday, 120 stocks hit new 52-week highs.
Benzinga · 05/18 14:44
Stocks That Hit 52-Week Highs On Wednesday
This morning 35 companies set new 52-week highs.
Benzinga · 05/13 14:35
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 11:40
Protalix Fabry Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 05/12 18:09
Stocks That Hit 52-Week Highs On Tuesday
Tuesday morning saw 85 companies set new 52-week highs.
Benzinga · 05/12 14:41
Edited Transcript of ATRC earnings conference call or presentation 29-Apr-20 8:30pm GMT
Q1 2020 AtriCure Inc Earnings Call
Thomson Reuters StreetEvents · 05/12 02:42
Stocks That Hit 52-Week Highs On Monday
Monday's morning session saw 70 companies set new 52-week highs.
Benzinga · 05/11 14:29
AtriCure Announces $100M Common Stock Offering
Benzinga · 05/11 11:55
ArtiCure Announcds $100M Common Stock Offering
Benzinga · 05/11 11:53
Oppenheimer Maintains Outperform on AtriCure, Raises Price Target to $52
Oppenheimer maintains AtriCure (NASDAQ:ATRC) with a Outperform and raises the price target from $45 to $52.
Benzinga · 05/11 11:39
AtriCure Announces Proposed Public Offering of Common Stock
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell approxima
Business Wire · 05/11 11:16
SVB Leerink Reiterates Outperform on AtriCure, Raises Price Target to $55
SVB Leerink reiterates AtriCure (NASDAQ:ATRC) with a Outperform and raises the price target from $50 to $55.
Benzinga · 05/11 10:16
AtriCure (ATRC) Investor Presentation - Slideshow
Seeking Alpha - Article · 05/08 14:59
AtriCure Announces Results from CONVERGE IDE Clinical Trial
Business Wire · 05/08 13:47
AtriCure device demonstrates effectiveness in new way to treat irregular heartbeat
Seeking Alpha - Article · 05/08 13:23
AtriCure Reports Results From CONVERGE IDE Trial: 'study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure'
AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the results from the CONVERGE IDE clinical trial. This
Benzinga · 05/08 12:48
Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $45
Canaccord Genuity maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $41 to $45.
Benzinga · 04/30 16:35
AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virtual Meeting
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will host an analyst and institutional investor update webcast at 1:00 p.m. Eastern Tim
Business Wire · 04/30 12:30
AtriCure, Inc. (ATRC) CEO Michael Carrel on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 04/30 02:50